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Abstract
CD4+ CD25+ T regulatory cells are avidly studied because they
modulate immune responses. Their possible role in autoimmunity
and more specifically in rheumatoid arthritis (RA) has been
highlighted by a string of reports, one of which is in the last issue
of Arthritis Research & Therapy. There are, however, key questions
that have not yet been addressed before their use can be
considered as a real therapeutic option. The first is the actual, in a
clinical setting, efficacy of Treg to treat active chronic autoimmune
diseases such as RA. The second is how we can practically deliver
their therapeutic activity in patients. Once these points have been
addressed we will have a new and potentially very effective ‘magic
bullet’ for the treatment of chronic autoimmune diseases.
In recent years the T-regulatory (CD4+CD25+ Treg) storm
has remodelled the immunology landscape. Since the original
reports of a suppressive activity of CD4+CD25+ Treg, in the
mid-1980s, an exponential number of papers have appeared
in the literature. The employment of CD4+CD25+ Treg for
therapeutic purposes is now one of the ‘holy grails’ in
immunology and much effort is focused on the exploitation of
this therapeutic avenue. In the last issue of Arthritis Research
& Therapy, Frey and colleagues [1] provide an additional
piece to the CD4+CD25+ Treg jigsaw. In most autoimmune
diseases (in humans or in animal models) Treg have been
identified [2,3]. In all tested models these cells were capable
of preventing or partly inhibiting the induction of an
autoimmune response. The absence of Treg, either due to a
Foxp3 genetic defect such as that in patients with IPEX
(immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome) [4] or scurfy mice [5] or by means of
depletion with anti-CD25 monoclonal antibodies in animal
models, favours the initiation of a variety of autoimmune
diseases [3]. Conversely, the adoptive transfer of
CD4+CD25+ T cells prevents the induction of autoimmune
responses [3]. The important role of CD4+CD25+ Treg
during the induction phase of autoimmunity has also been
previously confirmed in collagen-induced arthritis [6], one of
the most widely used RA animal models [7].
Frey and colleagues [1] show that CD4+CD25+ Treg also
have a fundamental role in the experimental antigen-induced
arthritis. However, not all RA animal models seem to respond
to CD4+CD25+ Treg manipulation as described in proteo-
glycan-induced arthritis [8]. On this backdrop the paper by
Frey and colleagues represents only a minor blink of an eye in
the vast Treg literature, but Frey and colleagues introduce a
provocative ‘spin’ to their results as they question the
potential of the ‘therapeutic’ role of Treg on established
autoimmune diseases. In this model, adoptive transfer of
preactivated CD4+CD25+ Treg can prevent the induction of
autoimmunity but cannot ‘cure’ animals with ongoing
autoimmunity. Thus it seems that the thresholds to control
induction or progression (therapeutic action) of an
autoimmune process, by non-antigen-specific CD4+CD25+ T
cells, are significantly different. Frey and colleagues also
monitored the ‘homing’ of the CD4+CD25+ Treg and
detected an accumulation in the inflamed joints, thus
excluding the possibility that the lack of therapeutic activity
was due to the inability of CD4+CD25+ Treg to migrate into
the inflamed tissue. The authors also pointed out that a ‘true’
curative activity of CD4+CD25+ Treg has been reported only
in colitis animal models [9,10], although it could be argued
that experiments in an animal model of type 1 diabetes (T1D)
might also be considered curative [11].
What implications might this study have for autoimmune
diseases, and specifically for RA? A first message is that
when studying CD4+CD25+ Treg we have to bear in mind
the compartment (tissue) that Treg are obtained from. Indeed,
it is apparent that, to gain significant results, studies on
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CD4+CD25+ Treg should seek to investigate cells from the
inflamed tissue or the regional lymph nodes. A series of
reports in animal models of autoimmune diseases, such as
T1D [11,12], and also in cancer [13], have clearly demon-
strated this point. This indicates that it might be meaningless
to monitor peripheral levels of CD4+CD25+ Treg. However, in
humans there are obvious restrictions because access to the
inflamed tissues or regional lymph nodes is often
impracticable. The present study also indicates that, despite
the localized accumulation at the site of inflammation,
CD4+CD25+ Treg might not be sufficient to suppress an
ongoing chronic autoimmune inflammatory process.
This idea had already been hinted at by a series of studies in
RA and other chronic autoimmune joint inflammatory
diseases such as juvenile idiopathic arthritis and spondylo-
arthropathies, in which phenotype, distribution and functional
studies of CD4+CD25+ Treg have been performed [14–17].
In all these studies CD4+CD25+ Treg were detected in the
joints or synovial fluid of the patients. In these reports it was
also shown that the identified CD4+CD25+ Treg had a
suppressive function and accumulated in the inflamed joint
[14–17]. One of these studies even reported that
CD4+CD25+ Treg isolated from joints of patients with active
arthritis had a more powerful suppressor activity than
peripheral CD4+CD25+ Treg [17]. Thus, despite the
presence of an increased number of CD4+CD25+ Treg with
a powerful suppressor activity, RA is not suppressed but the
disease is instead very active. The authors provided a
startling explanation for this apparent incongruence, in their
discovery that tissue-infiltrating effector (pathogenic) T cells
were less prone to be ‘suppressed’ by CD4+CD25+ Treg
than resting or naive peripheral blood T lymphocytes [17].
This study therefore suggested that during a chronic
autoimmune inflammatory disease CD4+CD25+ Treg are
attracted to and accumulate where needed but fail to
suppress the autoimmune inflammation. These results
therefore further indicate, in keeping with the paper by Frey
and colleagues, that therapeutic use of CD4+CD25 Treg
might not be a feasible option.
However, a recent study has proposed that anti-tumour
necrosis factor (TNF)-α, a benchmark therapy for RA,
drastically influences the function of CD4+CD25+ Treg [18].
The crucial point of that study was that Treg isolated from
patients with active RA before treatment with anti-TNF-α
were unable to suppress proinflammatory cytokine secretion
from activated T cells and monocytes. After anti-TNF-α
treatment the ‘hibernated’ peripheral blood CD4+CD25+
Treg pool recovered and powerfully inhibited, as in healthy
controls, not only T cell proliferation but also the production
of TNF-α and interferon-γ [18]. However, the presence of
functionally efficient peripheral CD4+CD25+ Treg after anti-
TNF-α therapy might be due to a simple redistribution of
these cells, which accumulate in the joints during the active
phase of RA. It is indeed well known that anti-TNF-α
treatment decreases the infiltrate in joints. Furthermore, RA
patients relapse shortly after withdrawal of anti-TNF-α [19]
and thus, despite the dampening of joint inflammation and the
reinstatement of fully functional CD4+CD25+ Treg, RA is still
not cured. These strands of evidence seem to play down a
hypothetical therapeutic role of CD4+CD25+ Treg in RA.
Are there further possible avenues to be explored in the area
of CD4+CD25+ Treg? One possibility is to investigate the
use of antigen-specific CD4+CD25+ Treg. Indeed, it has
been reported that antigen-specific CD4+CD25 Treg,
generated and expanded in vitro, might tip the balance and
allow a true curative action in animal models of T1D [12], and
much work is now directed to this area [20]. Two recent
studies in T1D and experimental autoimmune encephalo-
myelitis have highlighted the potential of this option by
genetic manipulation of T cells [21,22]. However, this might
not be an easy road to follow in humans because not all
autoantigen-specific T cells seem to be effective in treating
an ongoing autoimmune disease as described in the T1D
model [22]. Therefore in humans such a prescreening of
effective genetically redirected autoantigen-specific T cells
might be a highly complex task that is not always easy to
achieve. However, in this context, recent studies on RA have
indicated that antigen-specific (HC-gp39) CD4+CD25+ Treg
might be deficient in patients in comparison with controls
[23]. A more recent study indicated that in a restricted group
of RA patients orally challenged with dnaJP1 (a peptide
derived from a bacterial heath shock protein) an increase in
CD4+ CD25+ Treg was induced, with evidence of a shift from
a proinflammatory profile to a potentially regulatory one [24].
Although both studies focused on peripheral blood T cells,
they provide encouraging new avenues for novel therapeutic
strategies in RA. Still, more work is required to establish
whether harnessing CD4+CD25+ Treg will represent a viable
therapy for RA and other autoimmune diseases in the future.
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